Herantis Pharma Oyj (HRTIS) - Net Assets
Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has net assets worth €1.75 Million EUR (≈ $2.04 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.11 Million ≈ $5.98 Million USD) and total liabilities (€3.36 Million ≈ $3.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Herantis Pharma Oyj liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.75 Million |
| % of Total Assets | 34.21% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.2% |
| 10-Year Change | -104.05% |
| Growth Volatility | 5662.29 |
Herantis Pharma Oyj - Net Assets Trend (2011–2024)
This chart illustrates how Herantis Pharma Oyj's net assets have evolved over time, based on quarterly financial data. Also explore Herantis Pharma Oyj (HRTIS) total assets for the complete picture of this company's asset base.
Annual Net Assets for Herantis Pharma Oyj (2011–2024)
The table below shows the annual net assets of Herantis Pharma Oyj from 2011 to 2024. For live valuation and market cap data, see HRTIS stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-243.00K ≈ $-284.09K |
-105.14% |
| 2023-12-31 | €4.73 Million ≈ $5.53 Million |
+7940.28% |
| 2022-12-31 | €-60.28K ≈ $-70.48K |
-110.88% |
| 2021-12-31 | €554.30K ≈ $648.04K |
-92.69% |
| 2020-12-31 | €7.59 Million ≈ $8.87 Million |
+309.90% |
| 2019-12-31 | €1.85 Million ≈ $2.16 Million |
+2173.10% |
| 2018-12-31 | €-89.29K ≈ $-104.39K |
-102.18% |
| 2017-12-31 | €4.09 Million ≈ $4.78 Million |
+159.72% |
| 2016-12-31 | €1.57 Million ≈ $1.84 Million |
-73.75% |
| 2015-12-31 | €6.00 Million ≈ $7.01 Million |
-72.38% |
| 2014-12-31 | €21.72 Million ≈ $25.39 Million |
+18000.96% |
| 2013-12-31 | €120.00K ≈ $140.29K |
+3656.58% |
| 2012-12-31 | €-3.37K ≈ $-3.94K |
+99.73% |
| 2011-12-31 | €-1.25 Million ≈ $-1.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Herantis Pharma Oyj's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7781675232.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €80.00K | % |
| Other Comprehensive Income | €79.75 Million | % |
| Total Equity | €-243.00K | 100.00% |
Herantis Pharma Oyj Competitors by Market Cap
The table below lists competitors of Herantis Pharma Oyj ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Melhus Sparebank
OL:MELG
|
$54.85 Million |
|
Tune Protect Group Bhd
KLSE:5230
|
$54.87 Million |
|
HRS Co. Ltd
KQ:036640
|
$54.87 Million |
|
HSS Engineers Bhd
KLSE:0185
|
$54.89 Million |
|
Bright Sheland International Co Ltd
TWO:4556
|
$54.78 Million |
|
Cingulate Inc
NASDAQ:CING
|
$54.76 Million |
|
Optivision Technology
TWO:3666
|
$54.75 Million |
|
Boreo Oyj
HE:BOREO
|
$54.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Herantis Pharma Oyj's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,726,353 to -243,000, a change of -4,969,353 (-105.1%).
- Net loss of 4,939,000 reduced equity.
- Other factors decreased equity by 30,353.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.94 Million | -2032.51% |
| Other Changes | €-30.35K | -12.49% |
| Total Change | €- | -105.14% |
Book Value vs Market Value Analysis
This analysis compares Herantis Pharma Oyj's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €-1.03 | €1.77 | x |
| 2012-12-31 | €0.00 | €1.77 | x |
| 2013-12-31 | €0.03 | €1.77 | x |
| 2014-12-31 | €7.92 | €1.77 | x |
| 2015-12-31 | €1.40 | €1.77 | x |
| 2016-12-31 | €0.36 | €1.77 | x |
| 2017-12-31 | €0.97 | €1.77 | x |
| 2018-12-31 | €-0.02 | €1.77 | x |
| 2019-12-31 | €0.30 | €1.77 | x |
| 2020-12-31 | €0.98 | €1.77 | x |
| 2021-12-31 | €0.05 | €1.77 | x |
| 2022-12-31 | €0.00 | €1.77 | x |
| 2023-12-31 | €0.27 | €1.77 | x |
| 2024-12-31 | €-0.01 | €1.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Herantis Pharma Oyj utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-435.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.32 Million |
| 2012 | 0.00% | -897289.91% | 0.00x | 0.00x | €-393.66K |
| 2013 | -650.84% | 0.00% | 0.00x | 22.01x | €-793.00K |
| 2014 | -38.47% | -1044500.00% | 0.00x | 1.36x | €-10.53 Million |
| 2015 | -267.44% | -820716.11% | 0.00x | 2.35x | €-16.64 Million |
| 2016 | -280.94% | -17494.40% | 0.00x | 6.48x | €-4.58 Million |
| 2017 | -52.93% | 0.00% | 0.00x | 2.83x | €-2.57 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | €-4.17 Million |
| 2019 | -432.47% | 0.00% | 0.00x | 5.98x | €-8.19 Million |
| 2020 | -120.64% | 0.00% | 0.00x | 2.16x | €-9.91 Million |
| 2021 | -4253.26% | 0.00% | 0.00x | 12.48x | €-23.63 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-9.32 Million |
| 2023 | 5.92% | 0.00% | 0.00x | 1.43x | €-192.80K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-4.91 Million |
Industry Comparison
This section compares Herantis Pharma Oyj's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,031,670
- Average return on equity (ROE) among peers: -39.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Herantis Pharma Oyj (HRTIS) | €1.75 Million | 0.00% | 1.92x | $54.84 Million |
| Nanoform Finland Plc (NANOFH) | $60.03 Million | -39.03% | 0.20x | $78.90 Million |
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more